TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23497676

Group type: EXPERIMENTAL
Intervention: Betaglucan
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sodium hyaluronate (Neoviderm®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitis vinifera A. s‐I‐M.t‐O.dij (Ixoderm®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alga Atlantica plus Ethylbisiminomethylguaicolo and Manganese Cloruro (Radioskin1®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metal Esculetina plus Ginko Biloba and Aloe vera (Radioskin 2®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Natural triglycerides‐fitosterols (Xderit®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Selectiose plus thermal water of Avene (Trixera+®)
Number of subjects: 100
Study: 21771709

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy with irinotecan, oxaliplatin, and cetuximab
Number of subjects: 48
Study: 19254623

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Health education classes (control)
Number of subjects: 15
Study: 17086891

Group type: EXPERIMENTAL
Intervention: Modified-release clarithromycin 1000mg once daily (AECMR)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Immediate-release clarithromycin 500mg twice daily (AECIR)
Number of subjects: 161
Study: 16343235

Group type: EXPERIMENTAL
Intervention: TEC (Epirubicin 60 mg/m² iv + Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: TC (Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Number of subjects: 1282
Study: 12525741

Group type: EXPERIMENTAL
Intervention: Graves' disease patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 16
Study: 10949157

Group type: EXPERIMENTAL
Intervention: Evaluation of functioning
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Neuropsychological symptomatology evaluation
Number of subjects: 1
Study: 7745788

Group type: EXPERIMENTAL
Intervention: Ulinastatin 300,000 units.day‐1 during intraoperative and postoperative three days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 10
Study: 2149704

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 200 mg/day for 6 months
Number of subjects: 114

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 114
Study: 7013301

Group type: EXPERIMENTAL
Intervention: Lithium carbonate and neuroleptics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 90
Study: 31251407

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (habitual care)
Number of subjects: 68
Study: 29086063

Group type: COMPARATOR
Intervention: Glasdegib 100 mg diHCl formulation (fasted)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glasdegib 100 mg small-particle size maleate formulation (fasted)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glasdegib 100 mg large-particle size maleate formulation (fed)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg large-particle maleate formulation (fasted) with rabeprazole
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glasdegib 50 mg oral solution (fasted)
Number of subjects: 34
Study: 25403438

Group type: EXPERIMENTAL
Intervention: Blastocyst transfer (day 5)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cleavage stage transfer (day 3)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Blastocyst transfer (day 5) in women 35 or older
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cleavage stage transfer (day 3) in women 35 or older
Number of subjects: 104
Study: 24152746

Group type: EXPERIMENTAL
Intervention: Empirical prediction models for α‐carotene
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Empirical prediction models for β‐carotene
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Empirical prediction models for β‐cryptoxanthin
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Empirical prediction models for lutein/zeaxanthin
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Empirical prediction models for lycopene
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Empirical prediction models for total carotenoids
Number of subjects: 4180
Study: 21569437

Group type: EXPERIMENTAL
Intervention: VC measured by ventilometer in preoperative patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: VC measured by inspirometer in preoperative patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: VC measured by ventilometer in postoperative patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: VC measured by inspirometer in postoperative patients
Number of subjects: 52
Study: 18155872

Group type: EXPERIMENTAL
Intervention: Brachial-basilic arteriovenous fistula (BBAVF)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Prosthetic brachial-antecubital forearm loop (PTFE loop)
Number of subjects: 105
Study: 16562408

Group type: EXPERIMENTAL
Intervention: Pro-designated driver messages
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Monetary rewards for driver sobriety
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Bracelet with 'designated driver'
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1412
Study: 12952499

Group type: EXPERIMENTAL
Intervention: ABI 007 260 mg/m(2) administered as a 30-minute infusion without steroid pretreatment
Number of subjects: 460

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m(2) administered over 3 hours with steroid pretreatment
Number of subjects: 460
Study: 11023500

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autografting
Number of subjects: 32
Study: 9160642

Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up study
Number of subjects: 49
Study: 1423182

Group type: EXPERIMENTAL
Intervention: GMCSF administered subcutaneously (SC) at 5 micrograms/kg twice daily for 14 days starting the day after chemotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GMCSF administered SC at 10 micrograms/kg daily for 20 days starting 2 days after chemotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GMCSF administered SC every 12 hours for 14 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Prechemotherapy priming with GMCSF twice daily for 4 days (days -6 to -3)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GMCSF administered SC at 5 micrograms/kg twice daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Moderate-dose GMCSF with antihistamines and ibuprofen
Number of subjects: 57
Study: 6374679

Group type: EXPERIMENTAL
Intervention: 1 g nabumetone twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 18
Study: 30386143

Group type: EXPERIMENTAL
Intervention: LVLC-CTU (80 kVp and 240 mgI/mL) with IR
Number of subjects: 299

Group type: COMPARATOR
Intervention: Conventional CTU (120 kVp and 350 mgI/mL) with filtered-back projection
Number of subjects: 299
Study: 27154481

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) via a multifaceted strategy (decision aid, support of IVF nurse, reimbursement for an extra treatment cycle)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard IVF care (Control group)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM)
Number of subjects: 222
Study: 25028951

Group type: EXPERIMENTAL
Intervention: Breath stacking technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Number of subjects: 30
Study: 22629840

Group type: EXPERIMENTAL
Intervention: 89Sr-chloride fractional injection (50 Mbk)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard 150 Mbk injection (Control)
Number of subjects: 50
Study: 20558431

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren and Valsartan
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Active therapy (Aliskiren, Valsartan, Combination)
Number of subjects: 1101
Study: 18377854

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia intervention 20 minutes before and throughout the surgical procedure
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia intervention
Number of subjects: 350
Study: 16160691

Group type: EXPERIMENTAL
Intervention: PTA + EBT (14 Gy applied by an 192Ir source)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PTA + EBT
Number of subjects: 60
Study: 12823307

Group type: EXPERIMENTAL
Intervention: Oral terbinafine for confirmed dermatophyte onychomycosis for 12 weeks
Number of subjects: 35
Study: 11880064

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (PPS) therapy at doses of 300, 600, or 900 mg/day for 32 weeks
Number of subjects: 377

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 377
Study: 10025931

Group type: EXPERIMENTAL
Intervention: HCQ 400 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: HCQ 800 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: HCQ 1200 mg/day
Number of subjects: 212

Group type: COMPARATOR
Intervention: Naproxen (1,000 mg/day)
Number of subjects: 212
Study: 7546934

Group type: EXPERIMENTAL
Intervention: High-dose botulinum toxin type A (240 units/session)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Medium-dose botulinum toxin type A (120 units/session)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose botulinum toxin type A (60 units/session)
Number of subjects: 51
Study: 2100355

Group type: EXPERIMENTAL
Intervention: 10-min aerobic exercise condition
Number of subjects: 57

Group type: COMPARATOR
Intervention: No-exercise control condition
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Digits backward problems during exercise
Number of subjects: 57

Group type: COMPARATOR
Intervention: Digits backward problems in no-exercise group
Number of subjects: 57
Study: 6452842

Group type: EXPERIMENTAL
Intervention: Ipratropium nasal spray (80 micrograms, 4 times daily for 1 week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 31705602

Group type: EXPERIMENTAL
Intervention: Emollients in Prinsepia utilis Royle
Number of subjects: 309

Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 309
Study: 31292987

Group type: EXPERIMENTAL
Intervention: CAF + CMX
Number of subjects: 24

Group type: COMPARATOR
Intervention: CAF alone (control)
Number of subjects: 24
Study: 27859599

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (avoided peanuts)
Number of subjects: 60
Study: 25671762

Group type: EXPERIMENTAL
Intervention: Shampoo 72 hours after surgical procedure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care (no shampooing)
Number of subjects: 53
Study: 24072451

Group type: EXPERIMENTAL
Intervention: Dronedarone (400 mg twice daily)
Number of subjects: 1405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1405
Study: 22936099

Group type: EXPERIMENTAL
Intervention: Predictable small perturbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictable large perturbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpredictable perturbations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (predictable perturbations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with PD (predictable perturbations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictably small-magnitude perturbations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (unpredictable perturbations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with PD (unpredictable perturbations)
Number of subjects: 0
Study: 18594127

Group type: EXPERIMENTAL
Intervention: Anterior/Posterior (A/P) training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medio/Lateral (M/L) training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 17332789

Group type: EXPERIMENTAL
Intervention: Non-dieting lifestyle intervention group (n = 17)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waiting list control group (n = 14)
Number of subjects: 31
Study: 15220949

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFA) - 33 g daily intake from partially hydrogenated soy oil containing 20 g of TFA
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) - 33 g daily intake from fish oil with approximately 4 g of n-3 PUFA
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control fat - 33 g daily intake of control fat
Number of subjects: 87
Study: 11205182

Group type: EXPERIMENTAL
Intervention: Controlled hyperventilation for 20 minutes
Number of subjects: 8
Study: 9924276

Group type: EXPERIMENTAL
Intervention: Control + 50 g sugarbeet fibre/d
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Control + 50 g commercial inulin/d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 7995207

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraduodenal lipid
Number of subjects: 0
Study: 3055689

Group type: EXPERIMENTAL
Intervention: Orchiectomy + flutamide
Number of subjects: 55

Group type: COMPARATOR
Intervention: Orchiectomy + estramustine
Number of subjects: 55
Study: 29747834

Group type: EXPERIMENTAL
Intervention: 0.8 mg folic acid + 10 mg enalapril
Number of subjects: 10789

Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 10789
Study: 27622219

Group type: EXPERIMENTAL
Intervention: Omega-3 (1000 mg capsules for 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24669829

Group type: EXPERIMENTAL
Intervention: AZD9164 (1000 μg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: AZD9164 (400 μg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: AZD9164 (2800 μg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 22104540

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training: 3 × 3 min of bilateral dynamic squat exercises on a side-alternating vibration platform at 24-26 Hz three times per week
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (CON): Same amount of exercise time without WBV
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 82
Study: 20573635

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (2 doses: 2 h before surgery and on first postoperative day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19039292

Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention program
Number of subjects: 591

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 591
Study: 16020749

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-saturated diet rich in alpha-linolenic acid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 120
Study: 15063960

Group type: EXPERIMENTAL
Intervention: Experiential learning seminar on breastfeeding (2 hours)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine antenatal care (Control)
Number of subjects: 73
Study: 10868864

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg) plus Metformin (500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metformin (500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9268758

Group type: EXPERIMENTAL
Intervention: Itraconazole 300 mg/day (Group 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cryosurgery (Group 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Itraconazole 300 mg/day followed by cryosurgery (Group 3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Itraconazole (Groups 1 and 3)
Number of subjects: 12
Study: 8096958

Group type: EXPERIMENTAL
Intervention: BEAM plus ABMT
Number of subjects: 40

Group type: COMPARATOR
Intervention: mini-BEAM
Number of subjects: 40
Study: 3955536

Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week for 16 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week for 16 weeks) plus vitamin A (100,000 IU/week for 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 3046484

Group type: EXPERIMENTAL
Intervention: Cephalexin hydrochloride (250 mg four times a day) in study A
Number of subjects: 343

Group type: COMPARATOR
Intervention: Cephalexin monohydrate (500 mg two times a day) in study A
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Cephalexin hydrochloride (500 mg two times a day) in study B
Number of subjects: 343

Group type: COMPARATOR
Intervention: Cephalexin monohydrate (250 mg four times a day) in study B
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Both treatments (cephalexin hydrochloride and cephalexin monohydrate)
Number of subjects: 343
Study: 30611273

Group type: EXPERIMENTAL
Intervention: Animation-enriched VP group (N=35)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Video group (N=37)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Static VP group (N=31)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 103
Study: 29256191

Group type: EXPERIMENTAL
Intervention: Glove groups (cold gloves layered under mittens, mittens, cold gloves)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Bare hands
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Other glove groups (examination gloves, flight gloves, leather gloves, glove liners, glove liners layered under leather gloves)
Number of subjects: 180
Study: 25951227

Group type: EXPERIMENTAL
Intervention: Anodal right/cathodal left tDCS stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anodal left/cathodal right tDCS stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 0
Study: 23283645

Group type: EXPERIMENTAL
Intervention: Structured isometric exercise program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simple hand exercise (control group)
Number of subjects: 50
Study: 21645018

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 313
Study: 19916311

Group type: EXPERIMENTAL
Intervention: Air-ozone baths (20 minutes, ozone concentration 8-10 mg/l, temperature 36 degrees C, 10 daily procedures)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (30 patients without operational treatment)
Number of subjects: 160
Study: 17137887

Group type: EXPERIMENTAL
Intervention: Fully vaccinated (FV)
Number of subjects: 5193

Group type: COMPARATOR
Intervention: Partially vaccinated (PV)
Number of subjects: 5193
Study: 11823663

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 degrees C)
Number of subjects: 12
Study: 10401508

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Enhanced Vocational Rehabilitation (EVR)
Number of subjects: 152
Study: 7580021

Group type: EXPERIMENTAL
Intervention: Low dose of hMG (75 IU/day) in desensitization protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low dose of hMG (75 IU/day) in flare-up protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desensitization protocol (group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flare-up protocol (group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Desensitization protocol (groups I and II)
Number of subjects: 30
Study: 2401707

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 6989227

Group type: EXPERIMENTAL
Intervention: Unmeasured diet with the single restriction of simple sugars
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exchange type American Diabetes Association diet (caloric defined)
Number of subjects: 30
Study: 29777354

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy using a head‐mounted display
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 0
Study: 27036360

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (40mcg/day per nostril) intranasal spray for 6 months, starting at postoperative week 3 after wound healing
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intranasal saline spray
Number of subjects: 70
Study: 25539418

Group type: EXPERIMENTAL
Intervention: Nobori drug-eluting stent
Number of subjects: 363

Group type: COMPARATOR
Intervention: TAXUS drug-eluting stent
Number of subjects: 363
Study: 23809343

Group type: EXPERIMENTAL
Intervention: Surfactant therapy (given prophylactically or in established RDS)
Number of subjects: 0
Study: 21084673

Group type: EXPERIMENTAL
Intervention: Modelflow method (arterial cannulation)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Modelflow method (Finometer)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Thermodilution
Number of subjects: 9
Study: 19242626

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 23
Study: 16567857

Group type: EXPERIMENTAL
Intervention: Bioengineered human dermal substitute
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 245
Study: 12663596

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 69

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 69
Study: 10830075

Group type: EXPERIMENTAL
Intervention: Desflurane 2.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural anesthesia (15 ml ropivacaine 7.5 mg/ml with fentanyl 100 micrograms)
Number of subjects: 50
Study: 8924951

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vivo mature oocytes
Number of subjects: 0